Skip to main content
VVOS
NASDAQ Industrial Applications And Services

Vivos Therapeutics Reports Q2 Loss, Going Concern Warning, and High-Cost Financing

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.34
Mkt Cap
$4.77M
52W Low
$0.271
52W High
$5.12
52W Position info
25% above low
Off High info
93% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

VVOS sits 25% above its 52-week low of $0.271.

Summary

Vivos Therapeutics' Q2 2026 10-Q shows a $5.5M loss, $1.8M cash, a going concern warning, and new high-interest loans. The Streeterville debt exchange terms are now quantified, adding dilution and lender control.


Key Events · Earnings and Guidance · VVOS

  • Q2 Net Loss and Cash Burn

    Net loss of $5.5 million for Q2 2026, with cash down to $1.8 million as of June 30, 2026. Management reiterates substantial doubt about the company's ability to continue as a going concern.

  • High-Cost Short-Term Loans

    Subsequent to quarter end, Vivos entered into two loans totaling $1.05 million (gross) at a combined effective interest rate of approximately 38%, maturing April 2027.

  • Streeterville Debt Exchange Quantified

    The previously announced debt exchange is now triggered: $3.2 million of senior debt converts into 1,812,031 common shares at $0.4139 per share and 2,500 shares of Series B Non-Convertible Preferred Stock at $1,000 per share. The preferred stock carries a 9% dividend and requires Streeterville consent for future financings over $2.5 million.

  • CFO Transition

    Bradford Amman resigned as CFO effective July 31, 2026. Roman Franklin was appointed CFO through a managed services agreement with The CFO Portal, LLC.


Analysis · VVOS · Industrial Applications And Services

A $5.5 million net loss for Q2 2026, with only $1.8 million in cash and a reiterated going concern warning, underscores the precarious financial position. The company also disclosed two short-term loans at a combined 38% effective interest rate and a CFO change. The debt exchange with Streeterville is now quantified: $3.2 million of debt converts into 1.8 million common shares at $0.4139 and 2,500 preferred shares, adding significant dilution and restrictive covenants. This filing confirms the high cost of survival financing.

At the time of this filing, VVOS was trading at $0.34 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.8M. The 52-week trading range was $0.27 to $5.12. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VVOS - Latest Insights

VVOS
Aug 11, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
7
VVOS
Aug 03, 2026, 5:29 PM EDT
Filing Type: 8-K
Importance Score:
7
VVOS
Jul 15, 2026, 5:07 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
VVOS
Jul 15, 2026, 4:23 PM EDT
Filing Type: 4
Importance Score:
8
VVOS
Jul 07, 2026, 5:33 PM EDT
Source: Wiseek News
Importance Score:
8